Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 12/20 | 0.42 |
| ▸ | F10 | P00742 | 7/20 | 0.40 |
| ▸ | GSK3B | P49841 | 6/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | WNT1 | P04628 | 6/20 | 0.38 |
| ▸ | CLK2 | P49760 | 1/20 | 0.37 |
| ▸ | CLK3 | P49761 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17027749 | 0.87 | F10 (0.48) | DYRK1AF10GSK3BWNT1CLK2 | |
| SCHEMBL18996612 | 0.86 | DYRK1A (0.48) | DYRK1AF10GSK3BABL1WNT1 | |
| SCHEMBL18979428 | 0.86 | DYRK1A (0.41) | DYRK1AF10GSK3BABL1WNT1 | |
| SCHEMBL18979453 | 0.85 | PIK3CA (0.46) | DYRK1AF10 | |
| SCHEMBL28754069 | 0.78 | F10 (0.44) | DYRK1AF10GSK3BWNT1CLK2 | |
| SCHEMBL23635161 | 0.77 | DYRK1A (0.44) | DYRK1AF10GSK3BABL1WNT1 | |
| SCHEMBL23635162 | 0.76 | DYRK1A (0.34) | DYRK1AGSK3BABL1 | |
| SCHEMBL23635137 | 0.76 | DYRK1A (0.39) | DYRK1AF10GSK3BABL1WNT1 | |
| SCHEMBL17027818 | 0.73 | F10 (0.54) | DYRK1AF10GSK3BWNT1CLK2 | |
| SCHEMBL17027858 | 0.73 | DYRK1A (0.47) | DYRK1AF10GSK3BABL1WNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034101-A1 | ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | FROST BIOLOGIC INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-12383533-B2 | Antimitotic amides for the treatment of cancer and proliferative disorders | FROST BIOLOGIC, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| CN-114634483-B | Antimitotic amides for the treatment of cancer and proliferative diseases | 弗洛斯特生物科技有限公司 | 2024-08-13 | — | — | CN | disclosed |
| CN-114634483-A | Antimitotic amides for the treatment of cancer and proliferative diseases | 弗洛斯特生物科技有限公司 | 2022-06-17 | — | — | CN | disclosed |
| US-20220008395-A1 | ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | FROST BIOLOGIC, INC. | 2022-01-13 | — | — | US | disclosed |
| US-11129813-B2 | Antimitotic amides for the treatment of cancer and proliferative disorders | FROST BIOLOGIC, INC. (US) | 2021-09-28 | — | — | US | disclosed |
| EP-3107909-B1 | ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | FROST BIOLOGIC INC (US) | 2021-07-14 | — | — | EP | disclosed |
| US-20200397758-A1 | Antimitotic Amides for the Treatment of Cancer and Proliferative Disorders | FROST BIOLOGIC, INC. | 2020-12-24 | — | — | US | disclosed |
| US-10772872-B2 | Antimitotic amides for the treatment of cancer and proliferative disorders | FROST BIOLOGIC, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20180325871-A1 | ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | FROST BIOLOGIC, INC. (US) | 2018-11-15 | — | — | US | disclosed |
| US-10016398-B2 | Antimitotic amides for the treatment of cancer and proliferative disorders | FROST BIOLOGIC, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170172984-A1 | ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | FROST BIOLOGIC, INC. (US) | 2017-06-22 | — | — | US | disclosed |
| EP-3107909-A2 | ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | Frost Biologic, Inc. (US) | 2016-12-28 | — | — | EP | disclosed |
| WO-2015127284-A2 | ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | FROST BIOLOGIC, INC. (US) | 2015-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220008395-A1 | ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | CCNA1, CCNE1, CCNB1 | DYRK1A 1713/4885F10 2263/4885GSK3B 4455/4885 |
| US-20260034101-A1 | ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | NCOR1, NR0B1, NCOR2 | DYRK1A 1592/4885F10 4190/4885GSK3B 2689/4885 |
| US-20180325871-A1 | ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | CCNA1, CCNE1, CCNB1 | DYRK1A 1713/4885F10 2263/4885GSK3B 4455/4885 |
| US-12383533-B2 | Antimitotic amides for the treatment of cancer and proliferative disorders | CCNA1, CCNE1, CCNB1 | DYRK1A 1713/4885F10 2263/4885GSK3B 4455/4885 |
| US-10016398-B2 | Antimitotic amides for the treatment of cancer and proliferative disorders | CCNA1, CCNE1, CCNB1 | DYRK1A 1713/4885F10 2263/4885GSK3B 4455/4885 |
| US-11129813-B2 | Antimitotic amides for the treatment of cancer and proliferative disorders | CCNA1, CCNE1, CCNB1 | DYRK1A 1713/4885F10 2263/4885GSK3B 4455/4885 |
| US-10772872-B2 | Antimitotic amides for the treatment of cancer and proliferative disorders | CCNA1, CCNE1, CCNB1 | DYRK1A 1713/4885F10 2263/4885GSK3B 4455/4885 |
| US-20200397758-A1 | Antimitotic Amides for the Treatment of Cancer and Proliferative Disorders | CCNA1, CCNE1, CCNB1 | DYRK1A 1713/4885F10 2263/4885GSK3B 4455/4885 |
| US-20170172984-A1 | ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | CCNA1, CCNE1, CCNB1 | DYRK1A 1713/4885F10 2263/4885GSK3B 4455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.